AD	1					

Award Number: W81XWH-11-1-0231

TITLE: Study of mTOR signaling inhibitors as potential treatment for TSC

PRINCIPAL INVESTIGATOR: Michel Roberge

CONTRACTING ORGANIZATION: The University of British Columbia

Vancouver, Canada V6T1Z3

REPORT DATE: July 2012

TYPE OF REPORT: Revised Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Form Approved REPORT DOCUMENTATION PAGE OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE 2. REPORT TYPE 3. DATES COVERED **Revised Annual** 1 July 2011 - 30 June 2012 July 2012 5a. CONTRACT NUMBER 4. TITLE AND SUBTITLE Study of mTOR signaling inhibitors as potential treatment for TSC 5b. GRANT NUMBER W81XWH-11-1-0231 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5d. PROJECT NUMBER Michel Roberge 5e. TASK NUMBER **Betty Diamond 5f. WORK UNIT NUMBER** E-Mail: michelr@mail.ubc.ca 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER University of British Columbia, The Vancouver V6T1Z3 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The goal in year 1 of this award was to determine the extent to which six drugs reduce or normalize the pathologically high mTORC1 activity seen in TSC-defective cells, to determine whether they can improve other abnormal phenotypes described for TSC-defective cells, and to select a candidate for proof of concept in animal studies in year 2. The effect of drugs on mTORC1 signaling, cell viability, serum-independent proliferation, p27 nuclear localization and cell motility were determined in TSC2^{+/+} and TSC2^{-/-} cells. Two drugs, nitazoxanide and tizoxanide, did not significantly inhibit mTORC1 in these cells. Three additional drugs, perhexiline, amiodarone and niclosamide appear too toxic to be viable drugs for treatment of tuberous sclerosis. Dronedarone is the only drug with potential for in vivo testing. 15. SUBJECT TERMS mTOR, dronedarone, p27, cytotoxicity, TSC 16. SECURITY CLASSIFICATION OF: 17. LIMITATION 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON

OF ABSTRACT

UU

a. REPORT

b. ABSTRACT

U

c. THIS PAGE

U

OF PAGES

24

USAMRMC

code)

19b. TELEPHONE NUMBER (include area

Table of Contents

	Page
Introduction	4
Body	4
Key Research Accomplishments	25
Reportable Outcomes	25
Conclusion	25
References	25
Appendices	25

Introduction

Tuberous sclerosis is a disease associated with abnormally high mTORC1 signaling. The goal of this research is to determine the extent to which five approved drugs and one active drug metabolite that are mTOR signaling inhibitors (niclosamide, perhexiline, amiodarone, dronedarone, nitazoxanide and its active metabolite tizoxanide,) can reduce or normalize the high mTORC1 activity seen in TSC-defective cells and can ameliorate other abnormal phenotypes described for TSC-defective cells, and to select the best drug candidate to determine whether mTORC1 inhibition and inhibition of the growth of TSC-defective cells can be achieved in vivo at tolerated drug doses.

Body

Specific Aim 1.1. Normalization of mTORC1 signaling in TSC-defective cells.

In previous experiments (Balgi, 2009), we had tested the effect of short-term exposure (4 h) to niclosamide, perhexiline, and amiodarone on mTORC1 signaling in TSC2+/+ and TSC2-/- cells. The amiodarone analog dronedarone was only approved by the FDA in 2009. We have now compared the effect of amiodarone and dronedarone on mTORC1 activity in TSC2+/+ and TSC2-/- cells. Dronedarone effectively reduced mTORC1 signaling at 3 μ M and higher concentrations as shown by reduction of the phosphorylation of the mTORC1 substrate S6 kinase at threonine 389, and by its increased electrophoretic mobility (Figure 1). It is considerably more potent than amiodarone, which inhibits mTORC1 signaling in the 10-30 μ M concentration range (Figure 1). This observation is relevant because dronedarone appears to be a substantially safer drug than amiodarone in humans.

Nitazoxanide and tizoxanide inhibit mTORC1 signaling in MCF-7 human breast cancer cells and THP1 human leukemia cells (Lam, 2012). We have tested them on TSC2^{+/+} and TSC2^{-/-} mouse embryo fibroblasts. Neither drug showed significant inhibition of mTORC1 signaling in these cells (Figure 2). Nitazoxanide and tizoxanide were therefore excluded as potential therapeutics for tuberous sclerosis and they were not studied further.

We next tested the effect of niclosamide, perhexiline, amiodarone and dronedarone on mTORC1 signaling during long-term exposure (72h). By 72 h, mTORC1 signaling had returned to untreated levels for all drugs unlike rapamycin, an irreversible mTORC1 inhibitor used as a positive control in these experiments (Figure 3). The results indicate that mTORC1 inhibition by these four drugs is reversible and that the drugs may be metabolically inactivated during long term exposure.

We next determined the effects of the drugs on cell viability. There was no significant reduction in cell viability during 4 h exposure to the drugs except at the highest concentrations of perhexiline and dronedarone (10 μ M; Figure 4).

Therefore, during 4 h exposure, niclosamide, amiodarone and dronedarone significantly inhibited mTORC1 signaling in TSC2-/- cells at concentrations that are not toxic (10 μ M niclosamide, 30 μ M amiodarone and 3 μ M dronedarone). By contrast, perhexiline was toxic to cells at the concentration that inhibits mTORC1 signaling (10 μ M), indicating that it is less promising as a drug candidate for treatment of tuberous sclerosis.

The effect of the drugs on cell viability was also measured during long term exposure (5 days). Both TSC2+/+ and TSC2-/- cells showed reduced viability compared with untreated controls following treatment with niclosamide above 0.3 μ M, perhexiline above 3 μ M, amiodarone above 1 μ M and dronedarone above 1 μ M (Figures 5 and 6). Combined, these results indicate that the drugs do not kill cells but reduce their proliferation, which is expected of mTORC1 inhibitory drugs.

Specific Aim 1.2. Amelioration of abnormal phenotypes associated with the TSC defect.

A number of morphological and biochemical abnormalities have been reported in cultured TSC-defective cells. We examined whether the four drugs could ameliorate any of these abnormalities.

1- serum-independent proliferation

It has been reported that TSC2-/- cells are able to proliferate in medium lacking serum while TSC2+/+ cells are unable to do so. We observe that TSC2+/+ cells are more dependent on serum for proliferation than TSC2-/- cells (Figure 7). However, the proliferation of TSC2-/- cells was not completely independent of serum, rather the cells proliferated at a lower rate in the absence of serum than in its presence (Figure 7).

To determine whether the drugs reduced this difference and made TSC2-/- cell proliferation more sensitive to serum withdrawal, we treated TSC2+/+ cells and TSC2-/- cells with the drugs in the absence or presence of serum and viable cells were measured at 48 h (Figures 8 and 9). The decreased sensitivity of TSC2-/- cells to serum withdrawal was not corrected by exposure to niclosamide (Figure 8) at low concentrations that did not reduce the viability or proliferation of both cell lines. Higher concentrations of niclosamide caused reduced viability in both cell lines in serum and without serum. The other drugs also did not correct this defect (Figure 9).

2-reduced p27 expression and nuclear localization

It has been reported that TSC2-defective fibroblasts have reduced levels of the protein p27 and mislocalization of p27 from the nucleus to the cytoplasm. We used quantitative automated immunofluorescence microscopy to examine whether the drugs cause increased localization of p27 to the nucleus. Cells were treated with the drugs for 4 h, after which they were fixed with paraformaldehyde and incubated with p27 antibody followed by a fluorescently labeled secondary antibody. In the absence of drug treatment, p27 was localized to the cytoplasm and the nucleus in both cell lines (Figure 10).

To provide a quantitative measure, nuclear fluorescence intensity was determined in many cells in duplicate wells. Table 1 shows the average p27 fluorescence intensity (arbitrary fluorescence units) and the number of nuclei measured for each well and condition. Niclosamide caused an increase in nuclear p27 but this increase was more pronounced in TSC2+/+ cells than in TSC2-/- cells. Dronedarone caused an increase in nuclear p27 in both TSC2-/- and TSC2+/+ cells, and only at high concentrations that reduce cell viability. Amiodarone has not been tested.

3- reduced cell motility

TSC2-defective cells are reported to have reduced motility. We have used two assays to measure the effect of drugs on cell motility: a wound healing assay and a fluorescent bead track clearing assay. Both assays confirmed previous reports that TSC2-defective cells have reduced motility. In the wound healing assay, cells were cleared from a confluent monolayer and the width of the cleared zone (the wound) was measured over time. 5.5 h after wound generation TSC2+/+ cells had migrated into the gap left by the wound more than TSC2-/- cells (Figures 11, 12, 13). In the fluorescent bead track clearing assay, a uniform lawn of small fluorescent beads is deposited onto a cell culture plastic surface. Cells are then added and as they move along the surface, they phagocytose the beads, leaving a non-fluorescent track whose area can be measured by automated fluorescence microscopy. The tracks of TSC2-/- cells were smaller than those of TSC2+/+ cells (Figures 14, 15 and 16).

In the wound healing assay, drugs were added and the width of the cleared zone (the wound) was measured over time. In both $TSC2^{+/+}$ and $TSC2^{-/-}$ cells, perhexiline, niclosamide and dronedarone did not affect wound healing but amiodarone significantly inhibited wound healing (Figures 12 and 13)

In the bead clearing assay, the drugs had little or no effect on cell motility of either cell line except for nitazoxanide (10 μ M) which increased the motility of TSC2-/- cells (Figures 14, 15 and 16).

4- membrane ruffling defects

Membrane ruffling is a process that occurs at the leading edge of cells while they migrate. TSC2-/- cells have been reported to display reduced ruffling activity. Membrane ruffling is observed under the light microscope and is not a quantitative assay. Its main purpose here was to confirm results obtained in the cell motility assays. However, none of the drugs increased the migration of TSC2-/- cells in both the wound healing and the bead clearing assays. For this reason, the effects of the compounds on membrane ruffling were not tested.

5- Reduced PDGF-PI3K-Akt signaling This task has not yet been carried out.

In summary, although niclosamide, perhexiline, amiodarone and dronedarone were shown to inhibit mTORC1 signaling in TSC2-/- cells, none clearly ameliorates the phenotypic defects displayed by TSC2-/- cells. Two drugs, nitazoxanide and its active metabolite tizoxanide did not significantly inhibit mTORC1 signaling. Two drugs, perhexiline and amiodarone, inhibited mTORC1 signaling in TSC2-/- cells but they appear too toxic to be viable drug candidates for treatment of tuberous sclerosis. Niclosamide inhibited mTORC1 signaling in TSC2-/- cells. However, we have recently defined its mechanism of action: it inhibits mTORC1 by protonophoric activity (Fonseca et al., J. Biol. Chem. 287:17530, 2012). Protonophores are known to cause deleterious effects such as plasma membrane depolarization and mitochondrial uncoupling, making them unattractive as therapeutic agents. Dronedarone is therefore the only drug with potential for in vivo testing in Specific Aim 2.





Figure 1. Effect of amiodarone and dronedarone on mTORC1 signaling in TSC2^{+/+} and TSC2^{-/-} cells. The cells were incubated for a short period of time (4 h) with the indicated concentrations of drugs and the phosphorylation of the mTORC1 substrate S6K was measured by western blotting. This experiment was carried out three times, with similar results.






Figure 2. Effect of nitazoxanide and tizoxanide on mTORC1 signaling in TSC2^{+/+} and TSC2^{-/-} cells. The cells were incubated for a short period of time (4 h) with the indicated concentrations of drugs and the phosphorylation of the mTORC1 substrate S6K was measured by western blotting. This experiment was carried out twice, with similar results.





Figure 3. Effect of drugs on mTORC1 signaling in TSC2^{+/+} and TSC2^{-/-} cells. The cells were incubated for a long period of time (72 h) with the indicated concentrations of niclosamide, dronedarone, perhexiline, amiodarone or rapamycin, and the phosphorylation of the mTORC1 substrate S6K was measured by western blotting. This experiment was carried out twice, with similar results.







Figure 4. Effect of drugs on cell viability. TSC2^{+/+} and TSC2^{-/-} cells were incubated for 4 hours with the indicated micromolar concentrations of perhexiline (Per), niclosamide (Nic), amiodarore (Ami), dronedarone (Drone), rapamycin (Rap), and viable cell numbers were determined. Error bars represent positive and negative values of one standard deviation (N=3).







Figure 5. Effect of drugs on cell viability. $TSC2^{+/+}$ and $TSC2^{-/-}$ cells were incubated with the indicated micromolar concentrations of niclosamide or perhexiline and cell viability was measured after 5 days using the MTT assay. Error bars represent positive and negative values of one standard deviation (N=3).






Figure 6. Effect of drugs on cell viability. $TSC2^{+/+}$ and $TSC2^{-/-}$ cells were incubated with the indicated micromolar concentrations of amiodarone or dronedarone and cell viability was measured after 5 days using the MTT assay. Error bars represent positive and negative values of one standard deviation (N=3).




Figure 7. Effect of serum deprivation on the proliferation of TSC2^{+/+} and TSC2^{-/-} cells. Cells were exposed to culture medium containing 10% serum (Serum) or 0% serum (No Serum) for 24 h (upper panel) or 48 h (lower panel) and cell viability was determined using the MTT assay. Error bars represent positive and negative values of one standard deviation (N=3).




Figure 8. Effect of niclosamide on cell proliferation in the presence or absence of serum. TSC2^{+/+} and TSC2^{-/-} cells were exposed to the indicated concentrations of niclosamide for 48 h in medium containing 10% fetal bovine serum (Serum) or 0% serum (No Serum). Cell viability was measured using the MTT assay. Error bars represent positive and negative values of one standard deviation (N=3).




Figure 9. Effect of additional drugs on cell proliferation in the presence or absence of serum. TSC2^{+/+} and TSC2^{-/-} cells were exposed to the indicated concentrations of drugs for 48 h in medium containing different concentrations of fetal bovine serum (Serum). Cell viability was measured using the MTT assay. Error bars represent positive and negative values of one standard deviation (N=3).




Figure 10. Effect of dronedarone on the intracellular localization of p27. $TSC2^{+/+}$ and $TSC2^{-/-}$ cells were exposed to 0 μ M dronedarone (-) or 2 μ M dronedarone (+) dronedarone for 4 h and p27 was detected by immunofluorescence microscopy (green). The cells were also stained with the DNA dye Hoechst 33342 to visualize nuclei (blue).


Table 1 Effect of drugs on nuclear p27 localization

	nuclear p27					Dronedaro	ne					
	No drug	nic, 3µM	nic, 10µM	rapa, 30nM	rapa, 100nN	0.5 µM	1μM	2 μM	4µM	6 µM	8 µM	10µM
TSC2 +/+	259	605	815	244	215	267	287	351	349	441	801	289
	272	646	761	211	224	272	284	310	283	373	801	880
avg	265	626	788	228	220	269	286	330	316	407	801	585
	number of r	nuclei				Dronedaro	ne					
	No drug	nic, 3µM	nic, 10µM	rapa, 30nM	rapa, 100nN	0.5 µM	1μM	2 μM	4μM	6 µM	8 µM	10µM
TSC2 +/+	2874	1585	1281	3793	3782	3447	3354	3101	3372	2406	1069	34
	3223	1817	1479	4209	3551	4014	3466	3442	3654	2953	1682	276
avg	3049	1701	1380	4001	3667	3731	3410	3272	3513	2680	1376	155
	nuclear p27					Dronedaro	ne					
	No drug	nic, 3µM	nic, 10µM	rapa, 30nM	rapa, 100nN	0.5 µM	1µM	2 μM	4µM	6 µM	8 µM	10µM
TSC2 -/-	536	685	824	603		465			633	968		
	661	860	948	612	591	594	547	635	690	762	829	31
avg	598	772	886	607	566	529	545	587	662	865	720	56
	number of r	nuclei				Dronedaro	ne					
	No drug	nic, 3µM	nic, 10uM				1μM	2 μΜ	4µM	6 µM	8 µM	10µM
TSC2 -/-	398	252	191	395	370	676	648	492	422	123	147	346
	399			437	417	498		646	349	328		
01/0	200	227	400	446	204	507	640	ECO	200	226	200	225

Nuclear p27 numbers are arbitrary fluorescence intensity numbers in the nuclear region defined by DNA staining.

TSC2+/+ TSC2-/t=0h t=5.5h

Figure 11. Wound healing assay used to examine the effect of drugs on cell motility. Confluent TSC2^{+/+} and TSC2^{-/-} cells monolayers were scratched to generate a gap (t=0h) and cell movement to fill the gap was monitored at t=5h in the same area. The blue bars indicate the gap boundaries.







Figure 12. Effect of drugs on wound healing in TSC2^{+/+} cells. Cell migration into the cleared area was measured over time after addition of drugs t=0h.






Figure 13. Effect of drugs on wound healing in TSC2-/- cells. Cell migration into the cleared area was measured over time after addition of drugs t=0h.




Figure 14. Fluorescent bead clearing track clearing assay used to examine the effect of drugs on cell motility. TSC2^{+/+} and TSC2^{-/-} cells were deposited onto a lawn of fluorescent beads. As cells moved, they phagocytosed the beads, leaving a fluorescence-free track. After 5 hours, the cells were also stained with a fluorescent dye. The area cleared of fluorescent beads was measured by automated fluorescence microscopy.




Figure 15. Effect of drugs on fluorescent bead clearing. TSC2^{+/+} and TSC2^{-/-} cells were deposited onto a lawn of fluorescent beads and drugs were added for 5 hours. The area cleared of fluorescent beads was measured by automated fluorescence microscopy.




Figure 15 (continued).

viean iviouo	n Trac kArea						
		TSC2 +/+					
	Untreated	Rapamycin 3 nM	Rapamycin 30 nM	Untreated	Rapamycin 3 nM	Rapamycin 30 nM	
	5085	3307.29	3435.38	2958.03	2253.9	2296.35	
	2770.1	4104.81	3152.21	4323.79	2108.7	1842.03	
Average	3927.55	3706.05	3293.80	3640.91	2181.30	2069.19	
StdDev	1636.88	563.93	200.23	965.74	102.67	321.25	
lean Motio	n Trac kArea						
	Untreated	Dronedarone 3 µM	Amiodarone 30 µM	Perhexiline 3 µM	Niclosamide 3 µM	Nitazoxanide 10 µM	Tizoxanide 10 μM
	5810.04	5535.54	4426.19	4797.36	3607.18	6127.42	5410.41
TSC2 +/+	6379.52	6847.07	3472.17	4354.51	3601.54	6871.4	
Average	6094.78	6191.31	3949.18	4575.94	3604.36	6499.41	5410.41
StdDev	402.68	927.39	674.59	313.14	3.99	526.07	0.00
	Untreated	Dronedarone 3 µM	Amiodarone 30 µM	Perhexiline 3 µM	Niclosamide 3 µM	Nitazoxanide 10 µM	Tizoxanide 10 μM
TSC2 -/-	4442.67	3741.76	3245.58	4948.39	4537	6457.65	4829.96
	4453.42	3512.36	3747.14	3920.24	4474.66	5900.65	
Average	4448.05	3627.06	3496.36	4434.32	4505.83	6179.15	4829.96
	7.60	162.21	354.66	727.01	44.08	393.86	0.00

Figure 16. Effect of drugs on fluorescent bead clearing. The area cleared of fluorescent beads (Mean Motion Track Area, arbitrary units) was measured by automated microscopy from duplicate samples.

Key research accomplishments

• Identification of dronedarone as a candidate for in vivo studies described in Specific Aim 2, to be carried out in year 2 of this award.

Reportable outcomes

None

Conclusions

In year 1, the goal of Specific Aim 1 to test drugs in in cell culture in vitro to identify the best candidate for in vivo experiments was successfully achieved. Dronedarone was selected. It appears to be a promising candidate as it can inhibit mTORC1 signaling and increase nuclear localization of p27 at a concentration of 2 μ M (1.1 μ g/ml) in vitro, well within the 0.01 – 5 μ g/ml plasma concentrations observed during treatment of humans, and 0.02 – 500 μ g/ml observed in tissue recovered from treated animals (Benaim, 2012).

References

Balgi, A. D., Fonseca, B. D., Donohue, E., Tsang, T. C. F., Lajoie, P., Proud, C. G., Nabi, I. R. and Roberge, M. High content screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS ONE 4:e7124 (2009)

Lam, K.K.Y., Roberto Forestieri, R., Balgi, A. D., Zheng, X., Fonseca, B. D., Nodwell, M., Vollett, S., Anderson, H. J., Andersen, R. J., Av-Gay, Y. and Roberge, M. Nitazoxanide inhibits mTORC1 signaling, stimulates autophagy and inhibits the intracellular proliferation of *Mycobacterium tuberculosis*. PLoS Path. 8(5):e1002691 (2012)

Appendices

none